Vaxcyte to Present at the Guggenheim SMID Cap Biotech Conference
Rhea-AI Summary
Vaxcyte (Nasdaq: PCVX), a clinical-stage vaccine innovation company, has announced its participation in the Guggenheim SMID Cap Biotech Conference in New York. The company's management will engage in a fireside chat scheduled for Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
Investors and interested parties can access a live webcast of the presentation through the Investors & Media section of Vaxcyte's website at investors.vaxcyte.com. The webcast recording will remain available for approximately 30 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction – PCVX
On the day this news was published, PCVX declined 3.95%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN CARLOS, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference in New York on Thursday, February 6, 2025 at 9:30 a.m. ET / 6:30 a.m. PT.
A live webcast of the fireside chat can be accessed through the Investors & Media section of the Company’s website at http://investors.vaxcyte.com. A replay of the webcast will be available for approximately 30 days following the conference.
About Vaxcyte
Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. VAX-31 is a 31-valent, carrier-sparing PCV being developed for the prevention of IPD in adults and infants and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, the Company’s 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market and is currently being evaluated in a Phase 2 infant study. Both VAX-31 and VAX-24 are designed to improve upon the standard-of-care PCVs by covering the serotypes in circulation that are responsible for a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination practice.
Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF™ cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease; and VAX-GI, a vaccine candidate designed to prevent Shigella. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit www.vaxcyte.com.
Contacts:
Jennifer Zibuda, Senior Director, Investor Relations
Vaxcyte, Inc.
860-729-8902
investors@vaxcyte.com
FAQ
When is Vaxcyte (PCVX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors watch Vaxcyte's (PCVX) Guggenheim Conference presentation?
How long will Vaxcyte's (PCVX) Guggenheim Conference presentation be available for replay?
What type of presentation will Vaxcyte (PCVX) give at the Guggenheim SMID Cap Biotech Conference?
